Due to recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the homepage of the official account to get the latest trends and expert insights in the digital healthcare industry第一时间!
01 Global Digital Health Investment and Financing Overview
Non-Opioid Painkiller Developer Latigo Biotherapeutics Secures $150 Million in Series B Funding
On March 17, Latigo Biotherapeutics, a developer of non-opioid pain medications, secured $150 million in Series B financing led by a fund managed by Blue Owl Capital, with participation from Deep Track Capital, Access Biotechnology, and others. The funds will be used to advance the development of non-opioid pain medications.AI-Driven Drug Discovery Platform and Biotech Company Insilico Medicine Raises $110 Million in Series E FundingOn March 13, Insilico Medicine, an intelligent drug development platform and new drug research and development company, secured US$110 million in Series E funding led by Value Partners Group (HKG: 0806) through its private equity fund, in collaboration with Pudong Venture Capital, Pudong Development Group, Xici Venture Capital, and Yixing State-Owned Assets Control. The proceeds from this round will be used to drive breakthroughs in the upgrade of Insilico Medicine's artificial intelligence platform and innovation in its drug R&D pipeline, including enhancing its proprietary AI models and algorithms, as well as upgrading and expanding its leading automated robotic laboratory.Gene Therapy Developer Arbor Biotechnologies Secures $73.9 Million in Series C FinancingOn March 18, gene therapy developer Arbor Biotechnologies secured a $73.9 million Series C financing round, led by ARCH Venture Partners and TCGX. New investors QIA, Partners Investment, Revolution Partners, and Kerna Ventures, along with existing investors, participated in the funding. The proceeds will support the development of its novel gene-editing therapies targeting liver and central nervous system (CNS) diseases.TowardPi Medical Secures RMB 500 Million in Series E FinancingOn March 12, TowardPi, a high-end ophthalmic medical device developer, secured RMB 500 million in its Series E funding round, jointly invested by the Social Security Fund Zhongguancun Independent Innovation Special Fund (managed by Legend Capital), Beijing Robotics Industry Investment Fund, and Qiming Venture Partners. The proceeds will be used to expand TowardPi's product portfolio and strengthen its market presence globally.Neurostimulation Device Developer MicroTransponder Secures $65 Million in Series F FundingOn March 12, MicroTransponder, a developer of neurostimulation devices, secured $65 million in Series F funding led by U.S. Venture Partners, with participation from several other investors. The funds will be used to expand its FDA-approved Vivistim® Paired Vagus Nerve Stimulation (Paired VNS™) system, which has been clinically proven to significantly help chronic ischemic stroke survivors regain upper limb function.Innovative Drug R&D Platform Company Star Therapeutics Secures Nearly RMB 100 Million in Angel+ Round FinancingOn March 18, XingSaiRuiZhen, an innovation-driven pharmaceutical R&D platform company, secured nearly RMB 100 million in an angel+ funding round led by Fosun Pharma's New Drug Innovation Fund and Create-R Investment. The investment aims to support the company’s further development of its induced pluripotent stem cell (iPSC) regenerative medicine platform and accelerate the clinical translation process in the treatment of metabolic diseases and ophthalmic conditions.Medical Device Developer Perfuze Secures €22 Million in FinancingOn March 14, medical device developer Perfuze secured €22 million in funding from investors including Earlybird, EQT Life Sciences, Seroba, and SV Health. The proceeds will support the U.S. commercial rollout of Perfuze's two marketed products—the Zipline guiding catheter and the Millipede large-bore aspiration catheter—and advance the clinical progress of its pipeline products.Laplace Interventional, a developer of transcatheter tricuspid valve technologies, secures $22 million in Series C financingOn March 16, Laplace Interventional, a developer of transcatheter tricuspid valve technology, secured $22 million in Series C funding led by a global strategic investor, with participation from Aphelion Cardeation, Unorthodox Ventures, Engage Venture Partners, and others. The funds will be used to complete its Early Feasibility Study (EFS) and work towards obtaining approval for pivotal studies.Brain.space, a brain mapping data developer, secures $11 million in Series A fundingOn March 18, brain.space, a brain mapping data developer, secured $11 million in Series A funding led by Toyota Ventures, with participation from Mangrove Capital Partners and the Group Ventures. The Israel Innovation Authority also provided a non-dilutive grant of $3.5 million. The Series A funding will further advance brain.space's mission to develop large mind models (LMM) using standardized brain data, integrating human intelligence with machine learning to quantify an individual’s cognitive and emotional state, while generating tailored solutions that infuse human elements into digital systems.Diagnostic Solutions Provider C₂N Diagnostics Secures $10 Million in FinancingOn March 13, diagnostic solutions provider C₂N Diagnostics secured $10 million in funding from a consortium of Samsung C&T, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation. The funds will be used to expand the scale of its clinical laboratory services and further enhance the research, development, and commercialization capabilities of its Alzheimer's disease detection technology.Healthcare Data Platform Nimblemind.ai Secures $2.5 Million in FundingOn March 14, healthcare data platform Nimblemind.ai secured $2.5 million in funding, led by Bread & Butter Ventures with participation from Great Oaks Venture Capital. Nimblemind.ai is a developer of a technology platform designed to manage and enrich healthcare data.02 Digital Health Industry DynamicsNew Frontier Health/United Family Healthcare Deepens Cooperation with Warburg Pincus to Strengthen Position in High-End Private HealthcareOn March 14, New Frontier Health/United Family Healthcare announced the deepening of its strategic cooperation with Warburg Pincus, with Warburg Pincus further increasing its stake in United Family Healthcare. This collaboration will strengthen United Family Healthcare's leading position in China’s high-end private healthcare sector and enhance the accessibility of quality medical services. The United Family Healthcare network includes 11 hospitals and 24 clinics across multiple regions, serving over a million patients annually. Moving forward, United Family Healthcare will focus on advancing key strategic initiatives, including expanding service capacity, enhancing clinical capabilities, promoting research transformation, and driving digital innovation.03 Overview of Global Digital Health M&AMedical Device Service Provider and Distributor Healthcare Holding Schweiz Acquires Effectum CH-Rep AGOn March 17, Healthcare Holding Schweiz, a medical device service provider and distributor, acquired Effectum CH-Rep AG. This transaction marks the spin-off of all services provided by Effectum Medical AG as the authorized representative in Switzerland. Through this acquisition, Healthcare Holding Schweiz AG has strengthened its position as a comprehensive partner for global medical technology manufacturers. With its group of companies, it can now offer integrated services that include not only import and distribution but also full compliance with regulatory requirements.Endpoint Technology Solutions Provider Clario Acquires NeuroRxOn March 17, Clario, an endpoint technology solutions provider, acquired NeuroRx, a leader in imaging analysis with expertise in multiple sclerosis. This strategic acquisition strengthens Clario's leadership in the imaging field and further expands its capabilities in neuroscience. By enhancing its expertise in this critical therapeutic area, Clario can better support our clients in developing life-changing drugs.Northumbria Healthcare Trust Fund Acquires Health CallOn March 14, Northumbria Healthcare NHS Foundation Trust acquired the business of Health Call Solutions Limited to expand its software offerings and enhance patient healthcare. This move continues Northumbria Healthcare's digital strategy of developing and delivering services that support clinical staff and the public in accessing care, including the digitization of millions of health records and the creation of new systems to help medical teams work more efficiently.Life Science Lab Products and Services Supplier Arbor Biotechnologies Acquires Manvini BioOn March 13, Bioscience, a supplier of life science laboratory products and services, acquired Mannvini Bio. This acquisition will strengthen the production capabilities of Bioscience's laboratory consumables brand, BIOLEADER, providing strong support for its sustainable innovation and long-term development in the life sciences field.Arterial Network/Arterial Orange Industry Think Tank/Huaxing Capital/China Grand Health/Rock Health/Mobile Health News/Fierce Health, etc.
Compiled by: Huang Changjian
